Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson cOVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — International sales ($M) ($M)
Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule
Latest, Q4 2024
0
Period ended Dec 29, 2024
Change on a year earlier
-100.0%
44 in Q4 2023
History
20 quarters
Since Q1 2020
Sources
15
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — International sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2024 | Dec 29, 2024 | 0 | -100.0% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2024 | Sep 29, 2024 | 1 | -97.6% | Form 10-Q (filed 2024-10-23) ↗ |
| Q2 2024 | Jun 30, 2024 | 172 | -39.6% | Form 10-Q (filed 2024-07-25) ↗ |
| Q1 2024 | Mar 31, 2024 | 25 | -96.7% | Form 10-Q (filed 2024-05-01) ↗ |
| Q4 2023 | Dec 31, 2023 | 44 | -93.6% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2023 | Oct 1, 2023 | 41 | -91.6% | Form 10-Q (filed 2024-10-23) ↗ |
| Q2 2023 | Jul 2, 2023 | 285 | -42.9% | Form 10-Q (filed 2024-07-25) ↗ |
| Q1 2023 | Apr 2, 2023 | 747 | +95.5% | Form 10-Q (filed 2024-05-01) ↗ |
| Q4 2022 | Jan 1, 2023 | 689 | -51.0% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2022 | Oct 2, 2022 | 489 | +109.9% | Form 10-Q (filed 2023-10-27) ↗ |
| Q2 2022 | Jul 3, 2022 | 499 | +341.6% | Form 10-Q (filed 2023-07-31) ↗ |
| Q1 2022 | Apr 3, 2022 | 382 | – | Form 10-Q (filed 2023-04-28) ↗ |
| Q4 2021 | Jan 2, 2022 | 1,405 | – | Form 10-K (filed 2024-02-16) ↗ |
| Q3 2021 | Oct 3, 2021 | 233 | – | Form 10-Q (filed 2022-10-27) ↗ |
| Q2 2021 | Jul 4, 2021 | 113 | – | Form 10-Q (filed 2022-07-29) ↗ |
| Q1 2021 | Apr 4, 2021 | 0 | – | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Jan 3, 2021 | 0 | – | Form 10-K (filed 2023-02-16) ↗ |
| Q3 2020 | Sep 27, 2020 | 0 | – | Form 10-Q (filed 2021-10-29) ↗ |
| Q2 2020 | Jun 28, 2020 | 0 | – | Form 10-Q (filed 2021-07-29) ↗ |
| Q1 2020 | Mar 29, 2020 | 0 | – | Form 10-Q (filed 2021-04-30) ↗ |
Breakdown
What makes up covid-19 vaccine (ad26.cov2.s) [reported through fy2024q4] — international sales ($m)
Cite this data
StockData. (2026). Johnson & Johnson COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — International sales ($M) ($M), quarterly Q1 2020–Q4 2024 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_covid19_intl
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.